First oral biologic for psoriasis reaches patients, opening new front in autoimmune treatment

Overview

Updated May 30

For two decades, treating moderate-to-severe psoriasis required needles — self-injected drugs or clinic infusions many patients refused or abandoned. On March 18, 2026, the FDA approved ICOTYDE, a once-daily pill that blocks the IL-23 receptor like injectable biologics. In trials of roughly 2,500 patients, about 70 percent achieved clear or almost clear skin at 16 weeks, with side effects within 1.1 percentage points of placebo.

ICOTYDE is an engineered peptide designed to survive digestion and block IL-23 — not a conventional small-molecule drug. Johnson & Johnson is testing the same molecule in ulcerative colitis, Crohn's disease, and psoriatic arthritis. These conditions collectively affect tens of millions of people worldwide, and if the pill works, it could change the $30-billion autoimmune market away from injectable-first treatment.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

~70%

Patients achieving clear or almost clear skin at 16 weeks

Measured by Investigator Global Assessment score of 0 or 1 across Phase 3 trials

1.1%

Adverse event difference versus placebo

Side effect rates were nearly indistinguishable from placebo through 52 weeks of treatment

125M

People with psoriasis worldwide

Approximately 2-3% of the global population, with roughly 30% also developing psoriatic arthritis

$5B+

Projected peak annual sales

Johnson & Johnson's internal target, positioning the drug as a successor to the biosimilar-threatened Stelara franchise

~2,500

Patients enrolled across four Phase 3 trials

ICONIC-LEAD, ICONIC-ADVANCE 1 and 2, and ICONIC-TOTAL trials

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

People Involved

Dinesh V. Patel

Chief Executive Officer, Protagonist Therapeutics

Leading Protagonist through its first FDA approval and expanded pipeline

Jennifer Taubert

Executive Vice President and Worldwide Chairman, Innovative Medicine, Johnson & Johnson

Leading J&J's immunology commercial strategy

Joaquin Duato

Chief Executive Officer and Chairman, Johnson & Johnson

Positioning ICOTYDE as key growth driver for 2026

Mark Smythe

Co-founder, Protagonist Therapeutics

Developed the Vectrix peptide platform underlying ICOTYDE

Organizations Involved

Johnson & Johnson

Pharmaceutical company

Developer and commercial partner for ICOTYDE

Global pharmaceutical and medical device company whose Janssen subsidiary developed ICOTYDE through Phase 3 trials and will handle worldwide commercialization.

Protagonist Therapeutics

Biopharmaceutical company

Originator of icotrokinra; earning milestones and royalties

Biotech company specializing in constrained oral peptides, whose Vectrix platform enabled the first oral biologic to reach FDA approval.

U.S. Food and Drug Administration

Federal regulatory agency

Approved ICOTYDE for moderate-to-severe plaque psoriasis

Federal agency responsible for evaluating and approving new drugs for the U.S. market.

Bristol Myers Squibb

Pharmaceutical company

Maker of competing oral psoriasis drug Sotyktu, which ICOTYDE outperformed in head-to-head trials

Pharmaceutical company whose oral TYK2 inhibitor Sotyktu was the previous leading oral option for psoriasis until ICOTYDE demonstrated superiority in clinical trials.

Timeline

January 2003 March 2026

10 events Latest: March 18th, 2026 · 6 months ago

Tap a bar to jump to that date

March 2026
FDA approves ICOTYDE, first oral IL-23 blocker
Latest Approval

The FDA approved ICOTYDE (icotrokinra) for moderate-to-severe plaque psoriasis in adults and adolescents aged 12 and older. The first-in-class oral peptide targets the IL-23 receptor, previously reachable only by injectable biologics. Protagonist Therapeutics received a $50 million milestone payment.
March 18th, 2026
July 2025
J&J submits New Drug Application to FDA
Regulatory

Johnson & Johnson filed its New Drug Application for icotrokinra, seeking approval for moderate-to-severe plaque psoriasis in adults and adolescents.
July 1st, 2025
March 2025
ICOTYDE beats Sotyktu in head-to-head trials
Clinical Trial

Results from ICONIC-ADVANCE 1 and 2 showed icotrokinra was superior to deucravacitinib (Sotyktu), with 70 percent of patients achieving clear or almost clear skin versus roughly 40 percent for the competing oral drug.
March 1st, 2025
October 2023
Phase 3 ICONIC program launches
Clinical Trial

Johnson & Johnson initiated the Phase 3 ICONIC clinical trial program for icotrokinra, enrolling approximately 2,500 patients across four studies: ICONIC-LEAD, ICONIC-ADVANCE 1 and 2, and ICONIC-TOTAL.
October 1st, 2023
September 2022
Sotyktu approved as first oral TYK2 inhibitor
Approval

The FDA approved Bristol Myers Squibb's deucravacitinib (Sotyktu), the first oral TYK2 inhibitor for psoriasis. While closer to biologic efficacy than Otezla, it fell short of injectable standards.
September 9th, 2022
September 2017
Protagonist and J&J strike billion-dollar deal
Business

Protagonist Therapeutics and Johnson & Johnson's Janssen subsidiary signed a worldwide exclusive license agreement for icotrokinra. Protagonist received $50 million upfront and became eligible for up to $940 million in milestones.
September 19th, 2017
July 2017
Injectable IL-23-specific blockers arrive
Approval

Guselkumab (Tremfya) became the first IL-23-specific injectable biologic approved for psoriasis, followed by risankizumab (Skyrizi) in 2019. Both achieved skin clearance rates around 75-80 percent.
July 17th, 2017
March 2014
First targeted oral psoriasis drug approved
Approval

The FDA approved apremilast (Otezla), a PDE4 inhibitor and the first targeted oral therapy for psoriasis. Its efficacy was modest compared to injectable biologics.
March 21st, 2014
September 2009
Stelara approved, launching the IL-12/23 era
Approval

The FDA approved ustekinumab (Stelara), the first interleukin-12/23 blocker for psoriasis. The injectable drug eventually reached $11 billion in annual sales for Johnson & Johnson.
September 25th, 2009
January 2003
First biologic therapies approved for psoriasis
Milestone

The FDA approved alefacept and efalizumab, the first biologic drugs for psoriasis. TNF-alpha inhibitors followed, transforming treatment but requiring injections or infusions.
January 1st, 2003

Scenarios

ICOTYDE captures first-line oral position, reaching $5 billion in peak sales

Likely

Discussed by: J&J leadership at the January 2026 JPMorgan Healthcare Conference; GlobalData analysts projecting blockbuster status by 2029

Dermatologists adopt ICOTYDE as the default first oral therapy for moderate-to-severe psoriasis, displacing Sotyktu and expanding the treated population by converting injection-averse patients. Payers cover the drug without onerous prior authorization given its biologic-level efficacy and clean safety profile. Successful Phase 3 readouts in ulcerative colitis and Crohn's disease by 2028 multiply the addressable market. Over 50 percent of surveyed dermatologists already rank it as their top pipeline agent, and 70 percent envision first-line use.

Biosimilar competition and payer pushback limit uptake

Possible

Discussed by: Market analysts noting the 'cooler than expected' stock response on approval day; payer strategy consultants at Recon Strategy

Low-cost biosimilars of Stelara and eventually other injectable IL-23 blockers flood the market, and insurance companies mandate these cheaper injectables as first-line therapy before covering ICOTYDE. The drug's 30-minute fasting requirement and the modest efficacy gap versus top injectables like Skyrizi give payers justification to restrict access. ICOTYDE becomes a niche option for patients who specifically refuse injections rather than a broad market standard. Sotyktu's commercial underperformance — $291 million in 2025 versus projected $4 billion peak — serves as a cautionary precedent.

Next-generation oral competitors erode ICOTYDE's lead within three years

Possible

Discussed by: Alumis and Takeda leadership presenting late-stage TYK2 inhibitor data; BioPharma Dive analysts

Next-generation oral TYK2 inhibitors — Alumis's ESK-001 (envudeucitinib) and Takeda's zasocitinib — report Phase 3 results in 2026 that close the efficacy gap with ICOTYDE while potentially offering simpler dosing (no fasting requirement). If either matches or approaches ICOTYDE's skin clearance rates with comparable safety, the competitive landscape fragments before J&J can establish market dominance. The window for ICOTYDE to become the unchallenged oral standard narrows significantly.

Oral biologics expand across autoimmune diseases, reshaping the treatment paradigm

Possible

Discussed by: IQVIA analysts in their 2025 report on novel oral immunotherapies; J&J's immunology pipeline disclosures

ICOTYDE succeeds in Phase 3 trials for ulcerative colitis, Crohn's disease, and psoriatic arthritis, proving that oral IL-23 blockade works across multiple autoimmune conditions. Protagonist's pipeline of additional oral peptides — targeting IL-17, IL-4 receptor alpha, and GLP-1 — reaches clinical milestones. The combined effect shifts the default treatment paradigm for autoimmune diseases from injectable-first to oral-first, similar to how direct oral anticoagulants displaced warfarin and injectable heparin in cardiovascular medicine.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

2010-2020

Direct oral anticoagulants replace warfarin (2010-2020)

Starting with dabigatran (Pradaxa) in 2010, a wave of direct oral anticoagulants — including rivaroxaban (Xarelto) and apixaban (Eliquis) — replaced warfarin, a drug that required constant blood monitoring, dietary restrictions, and careful dose titration. The new pills offered fixed dosing with no monitoring.

Then

Adoption was rapid among cardiologists despite higher drug costs, driven by the dramatic reduction in monitoring burden for both patients and physicians.

Now

Within a decade, direct oral anticoagulants captured over 80 percent of new anticoagulant prescriptions. Eliquis became one of the world's best-selling drugs at over $20 billion annually. The transition demonstrated that reducing treatment burden can drive massive market shifts even when the new drugs are not clearly more effective.

Why this matters now

The anticoagulant transition is the clearest model for what ICOTYDE could achieve: a convenient oral alternative that captures market share primarily by reducing patient burden rather than by offering dramatically superior efficacy. The speed of the DOAC transition — under a decade to 80 percent share — suggests the psoriasis market could shift rapidly if payer barriers are manageable.

2011-2014

Hepatitis C: From interferon injections to oral cure (2011-2014)

For decades, hepatitis C was treated with interferon injections that caused severe flu-like side effects and cured fewer than half of patients. In 2013, Gilead Sciences launched Sovaldi (sofosbuvir), followed by Harvoni in 2014 — oral pills that cured hepatitis C in over 95 percent of patients within 8 to 12 weeks. Sovaldi generated $10.3 billion in its first full year on market.

Then

Patient demand overwhelmed payer budgets. Sovaldi's $84,000 list price for a course of treatment triggered a national debate about drug pricing even as it cured a previously intractable disease.

Now

The injectable interferon market collapsed almost entirely. Hepatitis C treatment became a cure rather than a chronic management regimen. The precedent demonstrated that oral drugs with dramatically superior convenience could rapidly displace entrenched injectable standards.

Why this matters now

ICOTYDE faces a similar dynamic: an oral drug entering a market dominated by effective but burdensome injectable therapies. The hepatitis C precedent suggests that if the efficacy gap is small enough, patient and physician preference for oral convenience can drive rapid market transformation — but pricing will be a central battleground.

September 2019

Oral semaglutide proves peptide pills are viable (2019)

Novo Nordisk won FDA approval for Rybelsus, the first oral formulation of a GLP-1 receptor agonist — the same class of drug as injectable Ozempic. The company used a novel absorption enhancer called SNAC to protect the peptide from stomach acid. Like ICOTYDE, Rybelsus required a 30-minute fast before eating.

Then

Initial enthusiasm was high, with 77 percent of surveyed patients preferring the oral form. That preference dropped to 46 percent once patients learned about the fasting requirement — a real-world friction that limited adoption.

Now

Rybelsus proved oral peptide delivery was commercially viable at scale, de-risking the concept for companies like Protagonist Therapeutics. However, injectable semaglutide (Ozempic, Wegovy) ultimately grew faster, partly because the fasting requirement reduced the convenience advantage of the oral form.

Why this matters now

ICOTYDE faces the same fasting-requirement challenge as Rybelsus. The oral semaglutide experience suggests that a pill format alone does not guarantee market dominance — the real-world convenience must be meaningfully better than the injectable alternative, not just theoretically better.